Repatha vs Lisinopril: Real-World Evidence Comparison

What Are These Two Drugs and Why Compare Them?

Repatha (evolocumab) and lisinopril occupy completely separate pharmacological categories, yet both appear on the medication lists of millions of patients with established cardiovascular disease or high cardiovascular risk. Understanding what each drug does, what evidence supports it, and when one might be preferred over the other requires separating their mechanisms before comparing outcomes.

Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on hepatocytes [1]. By blocking PCSK9, evolocumab increases LDL receptor recycling, dramatically lowering circulating LDL-C. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and ultimately systolic and diastolic blood pressure [2].

These drugs do not compete for the same indication in most patients. The comparison is clinically relevant because prescribers and patients sometimes ask whether one could replace the other in a cost-containment scenario, and because both are used simultaneously in high-risk atherosclerotic cardiovascular disease (ASCVD) management.

Mechanism Differences at a Glance

Evolocumab acts on lipid metabolism. Lisinopril acts on hemodynamic load. A patient with familial hypercholesterolemia and hypertension may genuinely need both, and no amount of LDL lowering substitutes for blood pressure control, nor does antihypertensive therapy lower LDL-C.

Why Real-World Evidence Matters Here

Randomized controlled trials (RCTs) enroll carefully selected populations. Real-world evidence (RWE) data capture the messier reality of polypharmacy, comorbidities, adherence, and socioeconomic variation. For a cost comparison like this one, RWE adherence data are particularly relevant because a cheaper drug that patients stop taking provides less protection than an expensive drug taken consistently.

FOURIER Trial: The Landmark Evidence for Evolocumab

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established ASCVD and LDL-C of 70 mg/dL or higher despite optimized statin therapy [1]. Patients received evolocumab 140 mg every two weeks or 420 mg monthly versus placebo.

After a median follow-up of 2.2 years, evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL to 30 mg/dL [1]. The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group versus 11.3% of the placebo group, a 15% relative risk reduction (HR 0.85, 95% CI 0.79-0.92, P<0.001) [1].

Secondary Endpoints in FOURIER

The key secondary endpoint of cardiovascular death, MI, or stroke was reduced by 20% (HR 0.80, 95% CI 0.73-0.88, P<0.001) [1]. The absolute risk reduction was 1.5 percentage points over 2.2 years, translating to a number needed to treat (NNT) of approximately 67 over that period. Benefit increased with longer duration of therapy, with the risk reduction in the second year exceeding that of the first.

Who Benefits Most From Evolocumab

Subgroup analyses from FOURIER show the greatest absolute benefit in patients with recent MI (within 2 years), multiple prior MIs, or peripheral artery disease alongside coronary artery disease [1]. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction identifies PCSK9 inhibitors as a Class I recommendation for patients with ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy [3].

ALLHAT Trial: The Definitive Evidence for Lisinopril in Hypertension

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is the largest antihypertensive RCT ever conducted, enrolling 33,357 participants aged 55 or older with hypertension and at least one additional coronary heart disease risk factor [2]. Lisinopril was compared with chlorthalidone (a thiazide diuretic) and amlodipine (a calcium channel blocker).

The primary outcome (fatal coronary heart disease or nonfatal MI) did not differ significantly between lisinopril and chlorthalidone (RR 0.99, 95% CI 0.91-1.08) [2]. However, chlorthalidone outperformed lisinopril on several secondary endpoints, particularly stroke (RR 1.15, 95% CI 1.02-1.30 favoring chlorthalidone) and heart failure [2].

What ALLHAT Actually Tells Clinicians

ALLHAT's results are often misread as evidence against lisinopril. The more accurate reading is that thiazide diuretics remain first-line for uncomplicated hypertension because they are equally effective at preventing hard outcomes at a fraction of the cost [2]. Lisinopril retains strong, guideline-supported preferred-agent status in specific populations.

Lisinopril's Preferred Indications Beyond ALLHAT

The 2023 ACC/AHA Hypertension Guideline gives ACE inhibitors a Class I recommendation as preferred agents in patients with hypertension plus chronic kidney disease (CKD), heart failure with reduced ejection fraction (HFrEF), or diabetes with albuminuria [3]. In these populations, RAAS blockade provides organ-protective benefits beyond blood pressure reduction alone. The guideline text states: "ACE inhibitors or ARBs are recommended to slow the progression of CKD in patients with hypertension and albuminuria" [3].

Real-World Evidence: Adherence, Persistence, and Outcomes

Adherence Data for Evolocumab

Real-world adherence to evolocumab tells a more complicated story than trial data suggest. A 2020 analysis of commercial insurance claims by Navar and colleagues found that only 40-50% of patients who initiated a PCSK9 inhibitor remained on therapy at 12 months, largely driven by prior authorization failures and out-of-pocket costs [4]. Among patients who maintained coverage and stayed on therapy, LDL-C reductions in practice (approximately 55-60%) were consistent with FOURIER results [4].

Adherence Data for Lisinopril

Generic lisinopril has among the highest adherence rates of any antihypertensive. A retrospective cohort study using the Optum claims database found 12-month persistence for ACE inhibitors at approximately 65-70%, higher than beta-blockers (58%) and comparable to ARBs [5]. The combination of low cost (as little as $4 per month at major pharmacy chains), once-daily dosing, and widespread familiarity among patients supports consistent use.

Real-World CV Outcomes Data

A 2021 population-based study published in the Journal of the American College of Cardiology examined evolocumab initiators in routine clinical practice and found median achieved LDL-C of 38 mg/dL, broadly consistent with FOURIER, with the caveat that only patients with more generous insurance coverage reached those levels systematically [6]. For lisinopril, decades of post-ALLHAT real-world data confirm that blood pressure control in the community remains suboptimal regardless of drug choice, with roughly 50% of treated hypertensive adults in the United States achieving the guideline target of below 130/80 mmHg [7].

Head-to-Head: Side Effect Profiles

Evolocumab Adverse Effects

Evolocumab has a notably clean safety profile in trial data. Injection-site reactions occur in approximately 2.1% of patients [1]. Neurocognitive adverse events, a concern raised early after PCSK9 inhibitor approval, were not significantly elevated in FOURIER (1.6% evolocumab vs. 1.5% placebo) [1]. New-onset diabetes was not increased. Musculoskeletal adverse effects, frequently reported with statins, were not elevated with evolocumab.

Lisinopril Adverse Effects

Lisinopril's most common adverse effect is a dry, persistent cough, which occurs in 5-20% of patients and is caused by bradykinin accumulation secondary to ACE inhibition [8]. Angioedema is rare but potentially life-threatening, occurring in approximately 0.1-0.5% of patients, with higher rates reported in Black patients [2]. Hyperkalemia is a real concern in patients with CKD or those co-prescribed potassium-sparing diuretics. Renal function must be monitored at baseline and after dose changes.

Dosing Regimens and Administration

Evolocumab Dosing

Evolocumab comes in two approved regimens: 140 mg subcutaneously every two weeks, or 420 mg subcutaneously once monthly. Both regimens use the Pushtronex on-body autoinjector or the SureClick autoinjector. Storage requires refrigeration at 2-8°C (36-46°F), though the drug can be kept at room temperature for up to 30 days [9]. For patients with homozygous familial hypercholesterolemia (HoFH), only the 420 mg monthly dose is studied and approved [9].

Lisinopril Dosing

Lisinopril is available in 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg oral tablets. For hypertension, the typical starting dose is 10 mg daily, titrated to 20-40 mg daily based on response [8]. For HFrEF, the starting dose is 2.5-5 mg daily with a target of 20-40 mg daily if tolerated [8]. Dose reductions are required in patients with a creatinine clearance below 30 mL/min.

When Would a Clinician Consider Switching or Combining?

The question of switching from Repatha to lisinopril, or vice versa, almost never applies in straightforward clinical practice because the drugs treat different problems. A more clinically accurate framing is:

Scenario 1: Patient on evolocumab who develops hypertension. Adding lisinopril (or another antihypertensive) is appropriate. There is no interaction between PCSK9 inhibitors and ACE inhibitors, and the combination is well-represented in FOURIER, where approximately 55% of enrolled patients were on an ACE inhibitor or ARB at baseline [1].

Scenario 2: Patient on lisinopril with uncontrolled LDL-C despite maximally tolerated statin. Adding evolocumab is consistent with Class I guideline recommendations for ASCVD patients with LDL-C at or above 70 mg/dL [3]. Lisinopril is continued for BP and organ-protective effects.

Scenario 3: Cost-driven substitution request. If a payer or patient asks whether lisinopril can replace Repatha, the answer is no. Lisinopril does not lower LDL-C, and evolocumab does not lower blood pressure. Substituting one for the other leaves an untreated cardiovascular risk factor.

Scenario 4: Patient with ACE inhibitor cough on lisinopril who also needs LDL lowering. The solution is switching lisinopril to an ARB (e.g., losartan), not to a PCSK9 inhibitor.

The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction states: "For patients with clinical ASCVD in whom LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy, ezetimibe is recommended, and if further LDL-C reduction is needed, a PCSK9 inhibitor is recommended (Class I, Level of Evidence: A)" [3].

Cost-Effectiveness and Access

Evolocumab Cost-Effectiveness

At list price, evolocumab costs approximately $550 per month or roughly $6,600 per year. A 2017 Institute for Clinical and Economic Review (ICER) analysis estimated a cost per quality-adjusted life year (QALY) of approximately $450,000 at list price, far exceeding the conventional $100,000-$150,000 willingness-to-pay threshold [10]. Since that analysis, manufacturer rebates and the introduction of a lower-dose 140 mg prefilled syringe have shifted the effective cost, but access remains primarily gated by insurance prior authorization and step-therapy requirements.

Lisinopril Cost-Effectiveness

Lisinopril is among the most cost-effective drugs in all of cardiovascular medicine. At $4-10 per month for the generic, the cost per QALY in hypertensive patients with diabetes or CKD is well below $10,000 by most analyses. The 2022 U.S. Preventive Services Task Force (USPSTF) recommends blood pressure screening and treatment for adults aged 18 and older with hypertension, citing clear net benefit [11].

Special Populations

Patients With Familial Hypercholesterolemia

For patients with heterozygous familial hypercholesterolemia (HeFH), PCSK9 inhibitors including evolocumab are guideline-recommended when LDL-C targets cannot be met with statins alone [3]. Lisinopril has no role in lowering LDL-C in FH. These patients may need both drugs if they also carry hypertension.

Patients With Chronic Kidney Disease

Lisinopril has a strong evidence base in CKD, particularly with proteinuria. ACE inhibitors reduce the rate of progression to end-stage renal disease in patients with diabetic nephropathy, as established in the MICRO-HOPE substudy of HOPE [12]. Evolocumab's FOURIER data included patients with eGFR as low as 20 mL/min/1.73 m², and exploratory analyses suggested similar LDL-C reductions without excess renal adverse events, though this population was small [1].

Patients With Heart Failure

Lisinopril (and other ACE inhibitors) carries a Class I recommendation in HFrEF from both ACC/AHA and European Society of Cardiology heart failure guidelines [3]. Evolocumab has not been studied in a primary HFrEF population, and LDL lowering in heart failure does not carry the same magnitude of evidence as RAAS inhibition.

Older Adults

Both drugs require attention in older adults. Lisinopril can cause first-dose hypotension, especially in volume-depleted patients, and should be started at 2.5-5 mg daily in this group [8]. Evolocumab's injection burden and cost may be barriers for older patients on fixed incomes, though patient assistance programs are available through Amgen.

Summary Table: Evolocumab vs. Lisinopril

| Feature | Evolocumab (Repatha) | Lisinopril | |---|---|---| | Drug class | PCSK9 monoclonal antibody | ACE inhibitor | | Primary indication | High LDL-C, ASCVD, FH | Hypertension, HFrEF, CKD | | Route | Subcutaneous injection | Oral tablet | | Frequency | Every 2 weeks or monthly | Once daily | | LDL-C effect | -59% (FOURIER) | No effect | | BP effect | Minimal | -10-15 mmHg systolic | | CV event reduction | 15% RRR (FOURIER) | Comparable to other antihypertensives (ALLHAT) | | Common side effects | Injection-site reactions (~2%) | Cough (5-20%), hyperkalemia | | Monthly cost | ~$550 (list) | ~$4-10 (generic) | | Interchangeable? | No | No |